REX vs SRPT · P/E 15, rev $642.5M vs rev $1.90B
REX American Resources Corporation (REX) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
REX American Resources Corporation (REX) is a chemicals company listed on NYSE.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported REX revenue for 2025-01-31 was $642.5M. Net income was $71.5M. Revenue was down 22.9% from 2024-01-31 to 2025-01-31. REX currently screens at market cap $1.43B and trailing P/E 15.5.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
REX currently screens at market cap $1.43B and trailing P/E 15.5. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the REX and SRPT stock pages for the full models.
Not investment advice.